US equities |
META $642.62 ▲+0.00% MU $877.55 ▲+0.00% TSLA $372.22 ▲+0.00% SPCX $147.49 ▲+0.00% NVDA $210.96 ▲+0.00% SNDK $1,238.03 ▲+0.00% NU $15.16 ▲+0.00% CRWV $54.23 ▼-0.01%
FinancialContent

Lexeo Therapeutics, Inc. - Common Stock (NQ:LXEO)

2.800 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexeo Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 ↗
LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results ↗
 
Via Benzinga
News headline image
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet ↗
 
Via Benzinga
News headline image
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout ↗
The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease. 
Via Investor's Business Daily
News headline image
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July ↗
 
Via Benzinga
Topics Stocks
News headline image
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor... 
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor... 
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
Via Benzinga
News headline image
Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Fastenal Company (NASDAQ: FAST) rose during Thursday’s session after the company reported... 
Via Benzinga
Topics Stocks
News headline image
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From LEXEO Therapeutics
Via GlobeNewswire
News headline image
Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones index gaining around 40 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From LEXEO Therapeutics
Via GlobeNewswire
News headline image
LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 ↗
Lexeo Therapeutics just reported results for the third quarter of 2023. 
Via InvestorPlace
News headline image
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
From LEXEO Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Pineapple Financial Drops In Trading Debut ↗
Shares of Pineapple Financial slipped over 25% in their trading debut following a downsized IPO. The tech-focused mortgage brokerage had cut the size of its offering from 1.25 million to 875,000 common... 
Via Talk Markets
Topics Initial Public Offering
< Previous 1 2 Next >